Infinity Pharmaceutical (INFI) Bounces after Vicious Sell-Off
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil settles lower as U.S. business activity cools, concerns over Middle East ease
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Infinity Pharma (INFI) Data on IPI-145 for Lymphomas
June 3, 2013 1:01 PM EDTInfinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with relapsed/refractory lymphoma, a group of potentially fatal hematologic malignancies, or blood cancers. Data from the study showed that IPI-145 was well tolerated and clinically active in patients with B-cell or T-cell lymphomas, including indolent non-Hodgkin lymphoma (iNHL), T-cell lymphoma, mantle cell lymphoma (MCL) and Hodgkin lymphoma (HL). These findings were presented today at the 2013 American Society of Clinical Oncology (ASCO)... More
Infinity Pharma (INFI) Data on IPI-145 for CLL 'Disappointing'
June 3, 2013 10:12 AM EDTShares of Infinity Pharmaceutical (NASDAQ: INFI) traded lower on Monday following updated Phase 1 data from an ongoing study of IPI-145.
Commenting, Piper Jaffray analyst Ian Somaiya called chronic lymphocytic leukemia results "disappointing." Specifically he was disappointed with lack of improvement in response rates even... More
Infinity Pharmaceuticals (INFI) Sells-Off Following ASCO
June 3, 2013 9:51 AM EDTInfinity Pharmaceuticals, Inc. (NASDAQ: INFI) is under heavy pressure early following Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), a potentially fatal... More
